You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,288,377


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,288,377
Title:Inhibitors of the interaction between MDM2 and p53
Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: ##STR00001## wherein n, s, t, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X, Y, Q, Z, G, E and D have defined meanings.
Inventor(s): Storck; Pierre-Henri (Ramsgate, GB), Schoentjes; Bruno (Bois-Guillaume, FR), Piettre; Arnaud Marcel Pierre (Sierentz, FR), Ermert; Philipp (Allschwil, CH), Poncelet; Virginie Sophie (Le Manoir sur Seine, FR), Csoka; Imre Christian Francis (Louviers, FR)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:12/678,680
Patent Claims:1. A compound of formula (I): ##STR00226## And any stereochemically isomeric form thereof, wherein n is 0, 1, 2, 3 or 4 and when n is 0 then a direct bond is intended, and wherein R.sup.1 on each carbon of the --(CHR.sup.1).sub.n-- group is each independently selected from hydrogen, halo, hydroxy, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, aryl, heteroaryl, C.sub.3-7cycloalkyl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl, and C.sub.3-7cycloalkyl-C.sub.1-6alkyl, any of said mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, aryl, heteroaryl, C.sub.3-7cycloalkyl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl or C.sub.3-7cycloalkylC.sub.1-6alkyl being optionally and independently substituted with one or more, substituents selected from hydroxy, amino, aryl and heteroaryl; s is 0 or 1 and when s is 0 then a direct bond is intended; t is 0 or 1 and when t is 0 then a direct bond is intended; R.sup.2 is selected from hydrogen, halo, cyano, amino; polyhaloC.sub.1-6alkyl; C.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl, aryl, heteroaryl, arylC.sub.1-6alkyl, heteroaryl-C.sub.1-6alkyl, C.sub.3-7cycloalkylC.sub.1-6alkyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C.sub.1-6alkyloxy, aryloxy, heteroaryloxy, C.sub.1-6alkylthio, arylthio, heteroarylthio, C.sub.1-6alkylcarbonyl, C.sub.3-7cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.3-7cycloalkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, C.sub.1-6alkylcarbonyloxy, C.sub.3-7cycloalkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonylamino, C.sub.1-6alkylcarbonylaminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl and mono- or di(C.sub.1-6alkyl)aminocarbonylC.sub.1-6alkyl, any of said groups being optionally and independently substituted with one or more, substituents selected from halo, hydroxy, cyano, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, aryl, heteroaryl, C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl and C.sub.1-6alkylcarbonyloxy; R.sup.3 is hydrogen; C.sub.1-6alkyl; aryl; heteroaryl; C.sub.3-7cycloalkyl; C.sub.1-6alkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; or C.sub.3-7cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; X is NR.sup.6, S or O; ##STR00227## is --CR.sup.7.dbd.CR.sup.8-- and then the dotted line is a bond, --CR.sup.7R.sup.9--CR.sup.8R.sup.10--, --C(.dbd.O)--CR.sup.8R.sup.10-- or --CR.sup.7R.sup.9--C(.dbd.O)--, wherein R.sup.7, R.sup.8, R.sup.9 or R.sup.10 are each independently selected from: hydrogen, halo, hydroxy, cyano; polyhaloC.sub.1-6alkyl; C.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl, aryl, heteroaryl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl, C.sub.3-7cycloalkylC.sub.1-6alkyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C.sub.1-6alkyloxy, C.sub.3-7cycloalkyloxy, aryloxy, heteroaryloxy, C.sub.1-6alkylthio, arylthio, heteroarylthio, C.sub.1-6alkylcarbonyl, C.sub.3-7cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.3-7cycloalkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, C.sub.1-6alkylcarbonyloxy, C.sub.3-7cycloalkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonylamino, C.sub.1-6alkylcarbonylaminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl and mono- or di(C.sub.1-6alkyl)aminocarbonylC.sub.1-6alkyl, any of said groups being optionally and independently substituted with one or more, substituents selected from halo, hydroxy, cyano, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, aryl, heteroaryl, C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl and C.sub.1-6alkylcarbonyloxy; or wherein any of R.sup.7 and R.sup.9 together, or R.sup.8 and R.sup.10 together form a bivalent radical selected from --(CH.sub.2).sub.2--O--(CH.sub.2).sub.2--, --(CH.sub.2).sub.2--S--(CH.sub.2).sub.2-- and --(CH.sub.2).sub.2--NR.sup.21--(CH.sub.2).sub.2-- wherein R.sup.21 is hydrogen, C.sub.1-6alkyl or C.sub.1-6alkyloxyalkyl; or wherein any of R.sup.7 and R.sup.9 together, or R.sup.8 and R.sup.10 together form a bivalent radical --(CH.sub.2).sub.m--, wherein m is 2, 3, 4, 5 or 6; -D- is --O; ##STR00228## is --CR.sup.19.dbd.C< and then the dotted line is a bond, --C(.dbd.O)--CH<, --C(.dbd.O)--N<, --CHR.sup.19--CH<, or --CHR.sup.19--N<, wherein each R.sup.19 is independently hydrogen or C.sub.1-6alkyl; R.sup.4 and R.sup.5 are each independently hydrogen, halo, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, cyano, cyanoC.sub.1-6alkyl, hydroxy, amino, C.sub.2-6alkenyl or C.sub.1-6alkyloxy, or R.sup.4 and R.sup.5 together form a bivalent radical selected from methylenedioxy or ethylenedioxy; R.sup.6 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl or C.sub.1-6alkyloxycarbonyl; Z is a radical selected from ##STR00229## wherein R.sup.11 or R.sup.12 are each independently selected from hydrogen, halo, hydroxy, amino, C.sub.1-6alkyl, nitro, polyhaloC.sub.1-6alkyl, cyano, cyanoC.sub.1-6alkyl, tetrazolo-C.sub.1-6alkyl, aryl, heteroaryl, heteroarylC.sub.1-6alkyl, aryl(hydroxy)-C.sub.1-6alkyl, heteroaryl(hydroxy)C.sub.1-6alkyl, arylcarbonyl, heteroarylcarbonyl, C.sub.1-6alkylcarbonyl, arylC.sub.1-6alkylcarbonyl, heteroarylC.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxy, C.sub.3-7cycloalkylcarbonyl, C.sub.3-7cycloalkyl(hydroxy)C.sub.1-6alkyl, arylC.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyloxyC.sub.1-6alkyl, hydroxyC.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.2-6alkenyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylcarbonyloxy, aminocarbonyl, hydroxyC.sub.1-6alkyl, aminoC.sub.1-6alkyl, hydroxycarbonyl, hydroxycarbonylC.sub.1-6alkyl and --(CH.sub.2).sub.v--(C(.dbd.O)).sub.r--(CHR.sup.18).sub.u--NR.sup.14R.sup- .15, wherein v is 0, 1, 2, 3, 4, 5, or 6 and when v is 0 then a direct bond is intended; r is 0 or 1 and when r is 0 then a direct bond is intended; u is 0, 1, 2, 3, 4, 5, or 6 and when u is 0 then a direct bond is intended; R.sup.18 is hydrogen or C.sub.1-6alkyl; R.sup.14 and R.sup.15 are each independently selected from hydrogen; C.sub.1-12alkyl; C.sub.1-6alkylcarbonyl; C.sub.1-6alkylsulfonyl; arylC.sub.1-6alkylcarbonyl; C.sub.3-7cycloalkyl; C.sub.3-7cycloalkylcarbonyl; --(CH.sub.2).sub.k--NR.sup.16R.sup.17; C.sub.1-12alkyl substituted with a substituent selected from hydroxy, hydroxycarbonyl, cyano, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyloxy, aryl or heteroaryl; or C.sub.3-7cycloalkyl substituted with a substituent selected from hydroxy, C.sub.1-6alkyloxy, aryl, amino, arylC.sub.1-6alkyl, heteroaryl or heteroarylC.sub.1-6alkyl, or R.sup.14 and R.sup.15 together with the nitrogen to which they are attached form morpholinyl; piperidinyl; pyrrolidinyl; piperazinyl; or piperazinyl substituted with a substituent selected from C.sub.1-6alkyl, arylC.sub.1-6alkyl, arylC.sub.1-6alkyloxycarbonyl, heteroarylC.sub.1-6alkyl, C.sub.3-7cycloalkyl and C.sub.3-7cycloalkylC.sub.1-6alkyl; wherein k is 0, 1, 2, 3, 4, 5, or 6 and when k is 0 then a direct bond is intended; R.sup.16 and R.sup.17 are each independently selected from hydrogen; C.sub.1-12alkyl; arylC.sub.1-6alkyloxycarbonyl; C.sub.3-7cycloalkyl; C.sub.1-12alkyl substituted with a substituent selected from hydroxy, C.sub.1-6alkyloxy, aryl, and heteroaryl; and C.sub.3-7cycloalkyl substituted with a substituent selected from hydroxy, C.sub.1-6alkyloxy, aryl, arylC.sub.1-6alkyl, heteroaryl, and heteroarylC.sub.1-6alkyl; or R.sup.16 and R.sup.17 together with the nitrogen to which they are attached form morpholinyl, piperazinyl, or piperazinyl substituted with C.sub.1-6alkyloxycarbonyl; R.sup.13 is hydrogen; C.sub.1-6alkyl; C.sub.3-7cycloalkyl; C.sub.1-6alkyl substituted with a substituent selected from hydroxy, amino, C.sub.1-6alkyloxy and aryl; or C.sub.3-7cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and C.sub.1-6alkyloxy; aryl is phenyl or naphthalenyl; each phenyl or naphthalenyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C.sub.1-6alkyl, amino, polyhaloC.sub.1-6alkyl and C.sub.1-6alkyloxy; and each phenyl or naphthalenyl can optionally be substituted with a bivalent radical selected from methylenedioxy and ethylenedioxy; heteroaryl is pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl or tetrahydrofuranyl; each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C.sub.1-6alkyl, amino, polyhaloC.sub.1-6alkyl, aryl, arylC.sub.1-6alkyl or C.sub.1-6alkyloxy; and each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with a bivalent radical selected from methylenedioxy or ethylenedioxy; an N-oxide form thereof or an addition salt thereof.

2. The compound according to claim 1 wherein R.sup.1 on each carbon of the --(CHR.sup.1).sub.n-- group is each independently selected from hydrogen, halo, hydroxy, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, aryl, heteroaryl, C.sub.3-7cycloalkyl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl, and C.sub.3-7cycloalkyl-C.sub.1-6alkyl, any of said mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, heteroaryl, C.sub.3-7cycloalkyl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl or C.sub.3-7cycloalkylC.sub.1-6alkyl being optionally and independently substituted with one or more, substituents selected from hydroxy, amino, aryl and heteroaryl; R.sup.2 is selected from hydrogen, halo, cyano, amino; polyhaloC.sub.1-6alkyl; C.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl, aryl, heteroaryl, arylC.sub.1-6alkyl, heteroaryl-C.sub.1-6alkyl, C.sub.3-7cycloalkylC.sub.1-6alkyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C.sub.1-6alkyloxy, aryloxy, heteroaryloxy, C.sub.1-6alkylthio, arylthio, heteroarylthio, C.sub.1-6alkylcarbonyl, C.sub.3-7cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.3-7cycloalkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, C.sub.1-6alkylcarbonyloxy, C.sub.3-7cycloalkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonylamino, C.sub.1-6alkylcarbonylaminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl and mono- or di(C.sub.1-6alkyl)aminocarbonylC.sub.1-6alkyl, any of said groups being optionally and independently substituted with one or more, substituents selected from halo, hydroxy, cyano, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, aryl, heteroaryl, C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl and C.sub.1-6alkylcarbonyloxy; X is NR.sup.6; ##STR00230## is --CR.sup.7.dbd.CR.sup.8-- and then the dotted line is a bond, --CR.sup.7R.sup.9--CR.sup.8R.sup.10--, --C(.dbd.O)--CR.sup.8R.sup.10-- or --CR.sup.7R.sup.9--C(.dbd.O)--, wherein R.sup.7, R.sup.8, R.sup.9 or R.sup.10 are each independently selected from: hydrogen, halo, hydroxy, cyano; polyhaloC.sub.1-6alkyl; C.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl, aryl, heteroaryl, heteroarylC.sub.1-6alkyl, C.sub.3-7cycloalkylC.sub.1-6alkyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C.sub.1-6alkyloxy, C.sub.3-7cycloalkyloxy, aryloxy, heteroaryloxy, C.sub.1-6alkylthio, arylthio, heteroarylthio, C.sub.1-6alkylcarbonyl, C.sub.3-7cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.3-7cycloalkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, C.sub.1-6alkylcarbonyloxy, C.sub.3-7cycloalkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonylamino, C.sub.1-6alkylcarbonylaminoC.sub.1-6alkyl, mono- or di(C.sub.1-6alkyl)aminocarbonyl and mono- or di(C.sub.1-6alkyl)aminocarbonylC.sub.1-6alkyl, any of said groups being optionally and independently substituted with one or more, substituents selected from halo, hydroxy, cyano, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, aryl, heteroaryl, C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl and C.sub.1-6alkylcarbonyloxy; or wherein any of R.sup.7 and R.sup.9 together, or R.sup.8 and R.sup.10 together form a bivalent radical selected from --(CH.sub.2).sub.2--O--(CH.sub.2).sub.2-- and --(CH.sub.2).sub.2--NR.sup.21--(CH.sub.2).sub.2-- wherein R.sup.21 is hydrogen, C.sub.1-6alkyl or C.sub.1-6alkyloxyalkyl; or wherein any of R.sup.7 and R.sup.9 together, or R.sup.8 and R.sup.10 together form a bivalent radical selected from --(CH.sub.2).sub.m--, wherein m is 2, 3, 4, 5 or 6; R.sup.4 and R.sup.5 are each independently hydrogen, halo, C.sub.1-6alkyl, cyano, cyanoC.sub.1-6alkyl, hydroxy, amino, or C.sub.1-6alkyloxy, or R.sup.4 and R.sup.5 together form a bivalent radical selected from methylenedioxy or ethylenedioxy; R.sup.6 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkylcarbonyl or C.sub.1-6alkyloxycarbonyl; Z is a radical selected from ##STR00231## wherein R.sup.11 or R.sup.12 are each independently selected from hydrogen, halo, hydroxy, amino, C.sub.1-6alkyl, nitro, polyhaloC.sub.1-6alkyl, cyano, cyanoC.sub.1-6alkyl, tetrazolo-C.sub.1-6alkyl, aryl, heteroaryl, heteroarylC.sub.1-6alkyl, aryl(hydroxy)-C.sub.1-6alkyl, heteroaryl(hydroxy)C.sub.1-6alkyl, arylcarbonyl, heteroarylcarbonyl, C.sub.1-6alkylcarbonyl, arylC.sub.1-6alkylcarbonyl, heteroarylC.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxy, C.sub.3-7cycloalkylcarbonyl, C.sub.3-7cycloalkyl(hydroxy)C.sub.1-6alkyl, arylC.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxyC.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.1-6alkyloxyC.sub.1-6alkyl, hydroxyC.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonylC.sub.2-6alkenyl, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylcarbonyloxy, aminocarbonyl, hydroxyC.sub.1-6alkyl, aminoC.sub.1-6alkyl, hydroxycarbonyl, hydroxycarbonylC.sub.1-6alkyl and --(CH.sub.2).sub.v--(C(.dbd.O)).sub.r--(CHR.sup.18).sub.u--NR.sup.14R.sup- .15, wherein v is 0, 1, 2, 3, 4, 5, or 6 and when v is 0 then a direct bond is intended; r is 0 or 1 and when r is 0 then a direct bond is intended; u is 0, 1, 2, 3, 4, 5, or 6 and when u is 0 then a direct bond is intended; R.sup.18 is hydrogen or C.sub.1-6alkyl; R.sup.14 and R.sup.15 are each independently selected from hydrogen; C.sub.1-12alkyl; C.sub.1-6alkylcarbonyl; C.sub.1-6alkylsulfonyl; arylC.sub.1-6alkylcarbonyl; C.sub.3-7cycloalkyl; C.sub.3-7cycloalkylcarbonyl; --(CH.sub.2).sub.k--NR.sup.16R.sup.17; C.sub.1-12alkyl substituted with a substituent selected from hydroxy, hydroxycarbonyl, cyano, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyloxy, aryl or heteroaryl; or C.sub.3-7cycloalkyl substituted with a substituent selected from hydroxy, C.sub.1-6alkyloxy, aryl, amino, arylC.sub.1-6alkyl, heteroaryl or heteroarylC.sub.1-6alkyl, or R.sup.14 and R.sup.15 together with the nitrogen to which they are attached form morpholinyl; piperidinyl; pyrrolidinyl; piperazinyl; or piperazinyl substituted with a substituent selected from C.sub.1-6alkyl, arylC.sub.1-6alkyl, arylC.sub.1-6alkyloxycarbonyl, heteroarylC.sub.1-6alkyl, C.sub.3-7cycloalkyl and C.sub.3-7cycloalkylC.sub.1-6alkyl; wherein k is 0, 1, 2, 3, 4, 5, or 6 and when k is 0 then a direct bond is intended; R.sup.16 and R.sup.17 are each independently selected from hydrogen; C.sub.1-6alkyl; arylC.sub.1-6alkyloxycarbonyl; C.sub.3-7cycloalkyl; C.sub.1-12alkyl substituted with a substituent selected from hydroxy, C.sub.1-6alkyloxy, aryl, and heteroaryl; and C.sub.3-7cycloalkyl substituted with a substituent selected from hydroxy, C.sub.1-6alkyloxy, aryl, arylC.sub.1-6alkyl, heteroaryl, and heteroarylC.sub.1-6alkyl; or R.sup.16 and R.sup.17 together with the nitrogen to which they are attached form morpholinyl, piperazinyl, or piperazinyl substituted with C.sub.1-6alkyloxycarbonyl.

3. The compound according to claim 1 or 2, wherein R.sup.1 on each carbon of the --(CHR.sup.1).sub.n-- group is each independently selected from hydrogen, hydroxy, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, arylC.sub.1-6alkyl and heteroarylC.sub.1-6alkyl; when any one R.sup.1 substituent in the --(CHR.sup.1).sub.n-- group is different from hydrogen, the other R.sup.1 substituents in the --(CHR.sup.1).sub.n-- group are each hydrogen; s is 0; t is 0 or 1; R.sup.2 is selected from hydrogen, halo, cyano, amino, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkyl, aryl, heteroaryl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, C.sub.1-6alkyloxy, arylC.sub.1-6alkyloxy, heteroarylC.sub.1-6alkyloxy, C.sub.1-6alkylthio, arylthio, C.sub.1-6alkylcarbonyl, hydroxyC.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkylcarbonyloxy, C.sub.1-6alkylcarbonylamino, morpholinyl, piperidinyl, pyrrolidinyl and piperazinyl; R.sup.3 is hydrogen or C.sub.1-6alkyl; ##STR00232## is --CR.sup.19.dbd.C< wherein R.sup.19 is hydrogen or C.sub.1-6alkyl; R.sup.4 and R.sup.5 are each independently hydrogen, halo, C.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, cyano, cyanoC.sub.1-6alkyl, hydroxy, amino, or C.sub.1-6alkyloxy; Z is a radical selected from (a-1), (a-2), (a-3), (a-4) and (a-5); R.sup.11 or R.sup.12 are each independently selected from hydrogen, hydroxy, amino, C.sub.1-6alkyl, nitro, polyhaloC.sub.1-6alkyl, cyano, aryl, arylC.sub.1-6alkyl, aryl(hydroxy)C.sub.1-6alkyl, arylcarbonyl, C.sub.1-6alkyloxy, C.sub.1-6alkyloxyC.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, aminocarbonyl, hydroxyl-C.sub.1-6alkyl, aminoC.sub.1-6alkyl, hydroxycarbonyl and --(CH.sub.2).sub.v--(C(.dbd.O)).sub.r--(CH.sub.2).sub.u--NR.sup.14R.sup.1- 5; v is 0 or 1; r is 0 or 1; u is 0; R.sup.14 and R.sup.15 are each independently selected from hydrogen, C.sub.1-6alkyl, --(CH.sub.2).sub.k--NR.sup.16R.sup.17 and C.sub.1-12alkyl substituted with hydroxy; R.sup.14 and R.sup.15 together with the nitrogen to which they are attached form pyrrolidinyl; k is 2; R.sup.16 and R.sup.17 are each independently C.sub.1-6alkyl; R.sup.13 is hydrogen or C.sub.1-6alkyl; aryl is phenyl or phenyl substituted with halo; and heteroaryl is pyridinyl, indolyl, oxadiazolyl or tetrazolyl; and each pyridinyl, indolyl, oxadiazolyl or tetrazolyl can optionally be substituted with one substituent selected from C.sub.1-6alkyl, aryl and arylC.sub.1-6alkyl.

4. The compound of claim 1, wherein n is 2; each R.sup.1 is hydrogen; s is 0; t is 0; R.sup.2 is selected from hydrogen halo, cyano, C.sub.1-6alkyl, hydroxyC.sub.1-6alkyl, C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonylamino and morpholinyl; R.sup.3 is hydrogen; ##STR00233## is --CH.dbd.C<; R.sup.4 and R.sup.5 are each independently hydrogen, C.sub.1-6alkyl or C.sub.1-6alkyloxy; R.sup.6 is hydrogen; Z is a radical selected from (a-1), (a-2) and (a-4), and R.sup.11 or R.sup.12 are each independently selected from hydrogen, hydroxy and hydroxyl-C.sub.1-6alkyl.

5. The compound of claim 1 wherein X is NR.sup.6.

6. The compound according to claim 1 wherein t is 0; s is 0; n is 2; X is NR.sup.6, S or O; R.sup.1 is hydrogen; R.sup.2 is hydrogen or halo; R.sup.3 is hydrogen; R.sup.4 and R.sup.5 are each independently hydrogen, C.sub.1-6alkyl or C.sub.1-6alkyloxy; R.sup.6 is hydrogen; ##STR00234## is --CR.sup.19.dbd.C< and then the dotted line is a bond, wherein R.sup.19 is hydrogen; Z is a radical of formula (a-2) or (a-4); R.sup.11 and R.sup.12 are each independently selected from hydrogen, hydroxyl and hydroxyC.sub.1-6alkyl.

7. The compound of claim 1 wherein ##STR00235## is --CR.sup.19.dbd.C< and then the dotted line is a bond, wherein R.sup.19 is hydrogen.

8. The compound of claim 1, wherein ##STR00236## is --CR.sup.7.dbd.CR.sup.8--, --CR.sup.7R.sup.9--CR.sup.8R.sup.10--, --C(.dbd.O)--CR.sup.8R.sup.10-- or --CR.sup.7R.sup.9--C(.dbd.O)--, and R.sup.7, R.sup.8, R.sup.9 or R.sup.10 are each independently selected from hydrogen, halo, hydroxy; perhaloC.sub.1-6alkyl; C.sub.1-6alkyl, C.sub.3-7cycloalkyl, arylC.sub.1-6alkyl, heteroarylC.sub.1-6alkyl, C.sub.1-6alkyloxy, aryl-C.sub.1-6alkyloxy, heteroarylC.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl, mono- or di(C.sub.1-6alkyl)amino, C.sub.1-6alkylcarbonylamino and morpholinyl, any of said groups optionally substituted with one or more, substituents selected from halo, hydroxy, amino, C.sub.1-6alkyl, polyhaloC.sub.1-6alkyl, aryl, heteroaryl and C.sub.1-6alkyloxy; or wherein any of R.sup.7 and R.sup.9 together, or R.sup.8 and R.sup.10 together form a bivalent radical --(CH.sub.2).sub.m--, wherein m is 2, 3, 4, 5 or 6.

9. The compound according to any of claims 1 to 8, wherein ##STR00237## is --CR.sup.7.dbd.CR.sup.8--, --CR.sup.7R.sup.9--CR.sup.8R.sup.10--, --C(.dbd.O)--CR.sup.8R.sup.10 or --CR.sup.7R.sup.9--C(.dbd.O)--, and R.sup.7, R.sup.8, R.sup.9 or R.sup.10 are each independently selected from hydrogen, halo, C.sub.1-6alkyl, perhaloC.sub.1-6alkyl, or wherein any of R.sup.7 and R.sup.9 together, or R.sup.8 and R.sup.10 together form a bivalent radical --(CH.sub.2).sub.m--wherein m is 2, 3, 4, 5 or 6.

10. The compound of claim 1 wherein ##STR00238## is --CH.sub.2--CH.sub.2--; --CH.sub.2--CH(CH.sub.3)--; --CH.sub.2--C(CH.sub.3).sub.2--; --CH.sub.2--CH(CH.sub.2OH)--; --CH.sub.2--C(CH.sub.3)(CH.sub.2CH.sub.3)--; --C(.dbd.O)--CH.sub.2--; --C(.dbd.O)--CH(CH.sub.3)--; --C(.dbd.O)--C(CH.sub.3).sub.2--; --C(.dbd.O)--CF.sub.2--; ##STR00239##

11. The compound according to claim 1, wherein the compound is selected from ##STR00240## ##STR00241## and any stereochemically isomeric form thereof; an N-oxide form thereof, or an addition salt thereof.

12. A pharmaceutical composition comprising pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of claim 1.

13. A method of treating cancer comprising administering a compound of claim 1 to a patient in need thereof, wherein the cancer is breast cancer, colorectal cancer, non-small cell lung cancer, prostate cancer, glioma, osteosarcoma- or acute myelogenous leukaemia.

14. A pharmaceutical composition comprising an anti-cancer agent and a therapeutically effective amount of a compound of claim 1, wherein the anticancer agent is selected from the group comprising platinum coordination compounds, taxane compounds, topoisomerase I inhibitors, topoisomerase II inhibitors, vinca alkaloids, nucleoside derivatives, alkylating agents, anthracylcine derivatives, IGF-1 receptor targets, tetracarcin derivatives, glucocorticoids, antibodies, estrogen receptor antagonist, estrogen receptor modulators, estrogen synthesis inhibitors, aromatase inhibitors, differentiating agents, DNA methyl transferase, antifolates, antibiotics, antimetabolites, apoptosis inducing agents, antiangiogenic agents, tubiline-binding agents, kinase inhibitors, farnesyltransferase inhibitors, histone deacetylase inhibitors, ubiquitin-proteasome inhibitors, yondelis, telomerase inhibitors, matrix metalloproteinase inhibitors, recombinant interleukins, MAPK inhibitors, retinoids, arsenic trioxide, asparaginase, steroids, gonadotropin releasing hormone agonist or antagonist, thalidomide, lenalidomide, Mercaptopurine, mitotane, pamidronate, pegademase, pegaspargase, rasburicase, BH3 mimetics, MEK inhibitors, colony-stimulating factor analogs.

15. A process for preparing a compound as claimed in claim 1, comprising a) reacting an intermediate of formula (II) with an intermediate of formula (III) or an appropriate acid addition salt thereof, wherein W is an appropriate leaving group ##STR00242## with the variables as defined in claim 1; b) reacting an intermediate of formula (XIX) wherein P represents a suitable protective group, with an intermediate of formula (III) or an appropriate acid addition salt thereof, wherein W is an appropriate leaving group ##STR00243## with the variables as defined in claim 1; c) reacting an intermediate of formula (XX) with an intermediate of formula (III) or an appropriate acid addition salt thereof, wherein W is an appropriate leaving group ##STR00244## with the variables as defined in claim 1; d) reacting an intermediate of formula (XXI) with a suitable deprotection agent for the alcohol function in the presence of a suitable solvent ##STR00245## with the variables as defined in claim 1; e) reacting an intermediate of formula (IV), wherein A is an appropriate leaving group, with an intermediate of formula (V ##STR00246## with the variables as defined in claim 1; f) reducing an intermediate of formula (VI) with lithium aluminium hydride in a suitable solvent ##STR00247## with the variables as defined in claim 1; g) reacting an appropriate carboxaldehyde of formula (VII), with an intermediate of formula (V), in the presence of an appropriate reducing reagent and a suitable solvent, ##STR00248## with the variables as defined in claim 1; h) reacting an intermediate of formula (II) with an appropriate carboxaldehyde of formula HC(.dbd.O)Z to obtain compounds of formula (I) wherein t is 1, herein referred to as compounds of formula (I-b); g) reducing an intermediate of formula (VIII) with lithium aluminium hydride in a suitable solvent ##STR00249## with the variables as defined in claim 1; h) converting a compound of formula (I) wherein ##STR00250## is --C(.dbd.O)--CR.sup.8R.sup.10 with R.sup.8 and R.sup.10 representing hydrogen, herein referred to as compounds of formula (I-f), into a compound of formula (I) wherein ##STR00251## is --CH.sub.2--CH.sub.2--, herein referred to as compounds of formula (I-g), by reaction with a suitable reducing agent, ##STR00252## with the variables as defined in claim 1.

Details for Patent 8,288,377

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2027-09-21
Servier Pharmaceuticals Llc ONCASPAR pegaspargase Injection 103411 02/01/1994 ⤷  Try a Trial 2027-09-21
Sanofi-aventis U.s. Llc ELITEK rasburicase For Injection 103946 07/12/2002 ⤷  Try a Trial 2027-09-21
Sanofi-aventis U.s. Llc ELITEK rasburicase For Injection 103946 01/06/2006 ⤷  Try a Trial 2027-09-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.